Ovarian Cancer

Higher Levels of Anti-CA15.3 and Anti-CA125 Linked to Increased Risk for Mucinous Epithelial Ovarian Cancer

Higher Levels of Anti-CA15.3 and Anti-CA125 Linked to Increased Risk for Mucinous Epithelial Ovarian Cancer

By

Researchers used the EPIC Cohort to identify whether anti-CA125 and anti-CA15.3 antibodies alone or in combination with antigens may determine epithelial ovarian cancer risk.

Ovarian Cancer Risk Reduced With Regular, Low-Dose Aspirin

Ovarian Cancer Risk Reduced With Regular, Low-Dose Aspirin

By

Although ovarian cancer risk may be reduced with regular use of low-dose aspirin, the use of nonaspirin analgesics may increase the risk of ovarian cancer among long-term, high-quantity users.

Ketogenic Diet May Benefit Ovarian, Endometrial Cancer Patients

Ketogenic Diet May Benefit Ovarian, Endometrial Cancer Patients

By

Women with ovarian or endometrial cancer who adhere to a ketogenic diet may benefit from a selective loss of fat mass and a reduction in fasting serum insulin, while still retaining lean mass.

Newer Hormonal Contraception May Cut Ovarian Cancer Risk

Newer Hormonal Contraception May Cut Ovarian Cancer Risk

Combined hormonal contraception use tied to lower risk; risk down with increasing duration of use.

Beyond <I>BRCA</i>: New Predisposition Genes Linked to Breast, Ovarian Cancers

Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers

By

Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.

Quantitative Image Marker Beneficial for Identifying Response to Postsurgical Chemotherapy in Ovarian Cancer

Quantitative Image Marker Beneficial for Identifying Response to Postsurgical Chemotherapy in Ovarian Cancer

By

Researchers identify a quantitative image marker that may be beneficial in predicting response to postsurgical chemotherapy in advanced-stage ovarian cancer.

Olaparib Treatment May Improve Health-Related Quality of Life in Germline <I>BRCA1/2</I>-Mutated Ovarian Cancer

Olaparib Treatment May Improve Health-Related Quality of Life in Germline BRCA1/2-Mutated Ovarian Cancer

By

Olaparib, may help to improve duration of good quality of life and quality-adjusted progression-free survival in germline BRCA1/2-mutated ovarian cancer.

Investigational Therapy Gets Fast Track Status for Recurrent Ovarian Cancer

Investigational Therapy Gets Fast Track Status for Recurrent Ovarian Cancer

By

A Phase 1 study in healthy volunteers showed a favorable safety profile with no serious adverse events.

Copy Number Abnormalities May Inform Survival, Drug Resistance

Copy Number Abnormalities May Inform Survival, Drug Resistance

For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.

Ultrasound Beneficial for Diagnosing Pure Clear Cell Carcinoma of the Ovary

Ultrasound Beneficial for Diagnosing Pure Clear Cell Carcinoma of the Ovary

By

In a multicenter study, researchers used high-quality ultrasound imaging to identify characteristics of pure ovarian clear cell carcinoma.

Higher Risk of In Situ Breast CA, Ovarian Tumors With Fertility Treatment

Higher Risk of In Situ Breast CA, Ovarian Tumors With Fertility Treatment

No increased risk of corpus uteri, invasive breast cancer for women undergoing assisted reproduction.

Quality of Life Maintained With Niraparib for Ovarian Cancer

Quality of Life Maintained With Niraparib for Ovarian Cancer

By

The ENGOT-OV16/NOVA trial showed improvements in progression-free survival in patients with ovarian cancer with and without the germline BRCA mutation.

Aspirin, Non-Aspirin NSAID Use May Improve Survival Outcomes in Ovarian Cancer

Aspirin, Non-Aspirin NSAID Use May Improve Survival Outcomes in Ovarian Cancer

Previous studies have suggested that analgesic medicine use may have a protective effect for patients with ovarian cancer.

Link for Asbestos-Free Talcum Powder, Cancer Not Clear

Link for Asbestos-Free Talcum Powder, Cancer Not Clear

Studies conducted in people have mixed results, with some indication of increased risk of ovarian cancer.

Progress Report in Cancer Control: How Are We Doing?

Progress Report in Cancer Control: How Are We Doing?

An analysis of population data on cancer incidence, survival, and mortality revealed that early interventions and improvements to treatments contributed to a 26% decline in cancer deaths from 1991 to 2015.

Chemotherapy With Bevacizumab May Improve Some Ovarian Cancer Outcomes, Worsen Others

Chemotherapy With Bevacizumab May Improve Some Ovarian Cancer Outcomes, Worsen Others

By

First-line chemotherapy in combination with bevacizumab, compared with chemotherapy alone, may benefit patients with ovarian cancer and elevated neutrophil-to-lymphocyte ratios.

No Difference in CEA vs CA125/CEA Ratio for Identifying Ovarian Masses

No Difference in CEA vs CA125/CEA Ratio for Identifying Ovarian Masses

By

No significant difference was identified in combination CA125/CEA ratio vs CEA alone in distinguishing ovarian neoplasms from ovarian metastases.

Avastin Plus ChemoTx Approved for Advanced Ovarian Cancer After Resection

Avastin Plus ChemoTx Approved for Advanced Ovarian Cancer After Resection

By

Study patients who received Avastin plus chemotherapy followed by Avastin alone, had a greater median PFS vs patients who received chemotherapy alone (18.2 months vs 12 months; hazard ratio [HR] 0.62, 95% CI, 0.52-0.75; P<.0001).

Mirvetuximab Gets Fast Track Status for Platinum-Resistant Ovarian Cancer

Mirvetuximab Gets Fast Track Status for Platinum-Resistant Ovarian Cancer

By

Mirvetuximuab soravtansine uses a humanized FRα-binding antibody to target antibody-drug conjugates specifically to FRα-expressing cancer cells and a potent anti-tumor agent, DM4, to kill the targeted cancer cells.

Prophylactic, Extended Carboplatin Infusion Not Linked to Lower HSR in Ovarian Cancer Patients

Prophylactic, Extended Carboplatin Infusion Not Linked to Lower HSR in Ovarian Cancer Patients

By

A prophylactic, graded, extended infusion of carboplatin, compared with a shorter, standard infusion, is not associated with a reduced rate of HSRs in women with recurrent ovarian cancer.

Severe Folate Deficiency Associated With Olaparib for Relapsed Ovarian Cancer

Severe Folate Deficiency Associated With Olaparib for Relapsed Ovarian Cancer

In a case study, olaparib was found to induce folate deficiency in most patients with relapsed ovarian cancer. Researchers discuss the significance of this adverse effect and how it was managed.

Ovarian Cancer Patients May Benefit From Trabectedin With PLD

Ovarian Cancer Patients May Benefit From Trabectedin With PLD

By

For patients with platinum-sensitive recurrent ovarian cancer, trabectedin plus PLD may be beneficial.

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.

Advanced Ovarian Cancer Survival Rates Longer After Primary Cytoreductive Surgery Compared With Neoadjuvant Chemotherapy

Advanced Ovarian Cancer Survival Rates Longer After Primary Cytoreductive Surgery Compared With Neoadjuvant Chemotherapy

By

Researchers found a superior survival rate in patients who received primary cytoreductive surgery as opposed to neoadjuvant chemotherapy for stage IIIC and IV high-grade serous ovarian carcinoma.

FDA Approves Multi-Cancer Treatment Drug

FDA Approves Multi-Cancer Treatment Drug

By

The FDA has approved Rubraca, a poly (ADP-ribose) polymerase inhibitor, to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Pap Tests May Help Diagnose Endometrial, Ovarian Cancers

Pap Tests May Help Diagnose Endometrial, Ovarian Cancers

Genetic mutations assays using PapSEEK may facilitate the detection of certain cancers using fluids from Pap tests.

Vigil Immunotherapy and PARP 7 Treatments for Patients with Ovarian Cancer

Vigil Immunotherapy and PARP 7 Treatments for Patients with Ovarian Cancer

Vigil immunotherapy is possible for women with recurrent ovarian cancer and PARP 7 may impact ovarian cancer survival, according to two studies presented in New Orleans.

Cooling therapy for hand-foot syndrome prevention, management

Cooling therapy for hand-foot syndrome prevention, management

For patients with ovarian cancer taking pegylated liposomal doxorubicin who have hand-foot syndrome, frozen gloves and socks is a safe method of treatment.

Metformin, statins not associated with ovarian cancer

Metformin, statins not associated with ovarian cancer

The incidence of ovarian cancer was not related to metformin or statin usage among women with type 2 diabetes.

Ovarian cancer may be paternally inherited

Ovarian cancer may be paternally inherited

By

The disease allele may be passed from affected grandmother to granddaughter through the father's inherited genes.

Sign Up for Free e-newsletters